Evidence map›Paper›PMID 42306082›Full record

ArticleMolecular therapy. Nucleic acids2026

CD39 mRNA therapy attenuates localized acute inflammation: A novel anti-inflammatory strategy using cationic nanoliposomes.

Naomi R Philosof, Aidan P G Walsh, Bangyan Xu, Anna M D Watson, Shulei Ren, Ludmilla Hann, Benedict Nathaniel, Anne Nguyen, Haikun Liu, Pengkai Shi and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Naomi R PhilosofMolecular Imaging and NanoTherapeutics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia.
Aidan P G WalshMolecular Imaging and NanoTherapeutics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia.
Bangyan XuMolecular Imaging and NanoTherapeutics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia.
Anna M D WatsonAtherothrombosis and Vascular Biology Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia.
Shulei RenMolecular Imaging and NanoTherapeutics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia.
Ludmilla HannDepartment of Thoracic and Cardiovascular Surgery, University Hospital Tübingen, Tübingen, Baden-Württemberg 72076, Germany.
Benedict NathanielMolecular Imaging and NanoTherapeutics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia.
Anne NguyenMolecular Imaging and NanoTherapeutics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia.
Haikun LiuMolecular Imaging and NanoTherapeutics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia.
Pengkai ShiMolecular Imaging and NanoTherapeutics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia.
Viktoria BongcaronMolecular Imaging and NanoTherapeutics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia.
Hung NguyenMolecular Imaging and NanoTherapeutics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia.
Jonathan NoonanCentre for Cardiometabolic mRNA Therapy, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia.
Meltem Avci-AdaliDepartment of Thoracic and Cardiovascular Surgery, University Hospital Tübingen, Tübingen, Baden-Württemberg 72076, Germany.
Karlheinz PeterCentre for Cardiometabolic mRNA Therapy, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia.
Mark Louis P VidallonMolecular Imaging and NanoTherapeutics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia.
Xiaowei WangMolecular Imaging and NanoTherapeutics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Messenger RNA (mRNA) therapeutics offer a promising strategy for treating inflammatory disease by enabling transient local expression of therapeutic proteins. CD39 (ectonucleoside triphosphate diphosphohydrolase-1) hydrolyzes pro-inflammatory ATP and ADP and plays a central role in localized immune regulation. We developed cationic nanoliposomes (NLps) for the delivery of CD39 mRNA and evaluated them in a murine model of localized inflammation induced by lipopolysaccharide and matrigel. Biodistribution studies showed substantial retention within the Matrigel matrix, with limited systemic distribution at 24 h. CD39 mRNA-NLps significantly reduced cellular infiltration at day 5, with decreased monocyte and macrophage staining via histological analysis. qPCR confirmed sustained local CD39 mRNA, while flow cytometry demonstrated increased CD39 protein staining in matrigel-derived immune cells, and phosphate release assays showed functional ectonucleotidase activity at the inflammatory site. Interleukin (IL)-6 levels were slightly reduced in matrigel extracts following treatment, supporting suppression of local inflammation. Hemocompatibility was confirmed using

Indexed as

anti-inflammatorycationic nanoliposomesCD39ENTPD1mRNA therapyMT: Delivery Strategies

Identifiers

PMID42306082
PMCPMC13267555

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.